Xavier Carette

Xavier Carette

Auto-generated profile, based on publicly available information

Xavier Carette

Division of Infectious Diseases, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2016 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
ASAtul K. Singh
Atul K. Singh
XCXavier Carette
Xavier Carette
LPLakshmi-Prasad Potluri
Lakshmi-Prasad Potluri
JSJared D. Sharp
Jared D. Sharp
RXRanfei Xu
Ranfei Xu
RHRobert N. Husson
Robert N. Husson
Despite many methodological advances that have facilitated investigation of Mycobacterium tuberculosis pathogenesis, analysis of essential gene function in this slow-growing pathogen remains difficult. Here, we describe an optimized CRISPR-based method to inhibit expression of essential genes based on the inducible expression of an enzymatically inactive Cas9 protein together with gene-specific guide RNAs (CRISPR interference). Using this system to target several essential genes of M. tuberculosis, we achieved marked inhibition of gene expression resulting in growth inhibition, changes in susceptibility to small molecule inhibitors and disruption of normal cell morphology. Analysis of expression of genes containing sequences similar to those targeted by individual guide RNAs did not reveal significant off-target effects. Advantages of this approach include the ability to compare inhibited gene expression to native levels of expression, lack of the need to alter the M. tuberculosis chromosome, the potential to titrate the extent of transcription inhibition, and the ability to avoid off-target effects. Based on the consistent inhibition of transcription and the simple cloning strategy described in this work, CRISPR interference provides an efficient approach to investigate essential gene function that may be particularly useful in characterizing genes of unknown function and potential targets for novel small molecule inhibitors.

3 May 2009 in Nature Medicine
Verified
Journal Article
Closed access
NWNicolas Willand
Nicolas Willand
BDBertrand Dirié
Bertrand Dirié
XCXavier Carette
Xavier Carette
PBPablo Bifani
Pablo Bifani
ASAmit Singhal
Amit Singhal
NWNicolas Willand
Nicolas Willand

21 March 2011 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MFMarion Flipo
Marion Flipo
MDMatthieu Desroses
Matthieu Desroses
NLNathalie Lecat-Guillet
Nathalie Lecat-Guillet
BDBertrand Dirié
Bertrand Dirié
XCXavier Carette
Xavier Carette
NWNicolas Willand
Nicolas Willand

2 May 2018 in mBio
Verified
Journal Article
Open access
PDF file
XCXavier Carette
Xavier Carette
JPJohn Platig
John Platig
DYDavid C. Young
David C. Young
MHMichaela Helmel
Michaela Helmel
AYAlbert T. Young
Albert T. Young
RHRobert N. Husson
Robert N. Husson
Tuberculosis is the leading killer among infectious diseases worldwide. Increasing multidrug resistance has prompted new approaches for tuberculosis drug development, including targeted inhibition of virulence determinants and of signaling cascades that control many downstream pathways. We used a multisystem approach to determine the effects of a potent small-molecule inhibitor of the essential Mycobacterium tuberculosis Ser/Thr protein kinases PknA and PknB. We observed differential levels of phosphorylation of many proteins and extensive changes in levels of gene expression, protein abundance, cell wall lipids, and intracellular metabolites. The patterns of these changes indicate regulation by PknA and PknB of several pathways required for cell growth, including ATP synthesis, DNA synthesis, and translation. These data also highlight effects on pathways for remodeling of the mycobacterial cell envelope via control of peptidoglycan turnover, lipid content, a SigE-mediated envelope stress response, transmembrane transport systems, and protein secretion systems. Integrated analysis of phosphoproteins, transcripts, proteins, and lipids identified an unexpected pathway whereby threonine phosphorylation of the essential response regulator MtrA decreases its DNA binding activity. Inhibition of this phosphorylation is linked to decreased expression of genes for peptidoglycan turnover, and of genes for mycolyl transferases, with concomitant changes in mycolates and glycolipids in the cell envelope. These findings reveal novel roles for PknA and PknB in regulating multiple essential cell functions and confirm that these kinases are potentially valuable targets for new antituberculosis drugs. In addition, the data from these linked multisystems provide a valuable resource for future targeted investigations into the pathways regulated by these kinases in the M. tuberculosis cell. IMPORTANCE Tuberculosis is the leading killer among infectious diseases worldwide. Increasing drug resistance threatens efforts to control this epidemic; thus, new antitubercular drugs are urgently needed. We performed an integrated, multisystem analysis of Mycobacterium tuberculosis responses to inhibition of its two essential serine/threonine protein kinases. These kinases allow the bacterium to adapt to its environment by phosphorylating cellular proteins in response to extracellular signals. We identified differentially phosphorylated proteins, downstream changes in levels of specific mRNA and protein abundance, and alterations in the metabolite and lipid content of the cell. These results include changes previously linked to growth arrest and also reveal new roles for these kinases in regulating essential processes, including growth, stress responses, transport of proteins and other molecules, and the structure of the mycobacterial cell envelope. Our multisystem data identify PknA and PknB as promising targets for drug development and provide a valuable resource for future investigation of their functions.

9 December 2011 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
XCXavier Carette
Xavier Carette
NBNicolas Blondiaux
Nicolas Blondiaux
EWEve Willery
Eve Willery
SHSylviane Hoos
Sylviane Hoos
NLNathalie Lecat-Guillet
Nathalie Lecat-Guillet
NWNicolas Willand
Nicolas Willand
Ethionamide is an antituberculous drug for the treatment of multidrug-resistant Mycobacterium tuberculosis. This antibiotic requires activation by the monooxygenase EthA to exert its activity. Production of EthA is controlled by the transcriptional repressor EthR, a member of the TetR family. The sensitivity of M. tuberculosis to ethionamide can be artificially enhanced using synthetic ligands of EthR that allosterically inactivate its DNA-binding activity. Comparison of several structures of EthR co-crystallized with various ligands suggested that the structural reorganization of EthR resulting in its inactivation is controlled by a limited portion of the ligand-binding-pocket. In silico simulation predicted that mutation G106W may mimic ligands. X-ray crystallography of variant G106W indeed revealed a protein structurally similar to ligand-bound EthR. Surface plasmon resonance experiments established that this variant is unable to bind DNA, while thermal shift studies demonstrated that mutation G106W stabilizes EthR as strongly as ligands. Proton NMR of the methyl regions showed a lesser contribution of exchange broadening upon ligand binding, and the same quenched dynamics was observed in apo-variant G106W. Altogether, we here show that the area surrounding Gly106 constitutes the molecular switch involved in the conformational reorganization of EthR. These results also shed light on the mechanistic of ligand-induced allosterism controlling the DNA binding properties of TetR family repressors.

1 May 2014 in Analytical Biochemistry
Verified
Journal Article
Closed access
CCCéline Crauste
Céline Crauste
NWNicolas Willand
Nicolas Willand
BVBaptiste Villemagne
Baptiste Villemagne
MFMarion Flipo
Marion Flipo
EWEve Willery
Eve Willery
NWNicolas Willand
Nicolas Willand